Scientists test groundbreaking RNA shot to stop malaria
NCT ID NCT05581641
Summary
This was a first-in-human study to test the safety and immune response of a new RNA-based malaria vaccine called BNT165b1. The trial enrolled 60 healthy adults to receive one of three dose levels or a placebo. The main goal was to find a safe and tolerable dose for future development.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty Research, LLC
Tempe, Arizona, 85281, United States
-
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada, 89119, United States
-
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, 37909, United States
-
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229, United States
-
University of Maryland, Center for Vaccine Development
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.